Asensus Surgical has received CE Mark for an expansion of machine vision capabilities on the previously cleared Intelligent Surgical Unit. With this CE Marking, the expanded ISU capabilities are now commercially available across all of the company’s key geographies, including the EU, Japan, and the U.S. In addition, this approval included a review of the Senhance Surgical System platform. The Senhance Surgical System is powered by the Intelligent Surgical Unit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ASXC:
- Asensus Surgical Receives CE Mark for Expanded Machine Vision Capabilities
- Asensus Surgical Provides Preliminary 2022 Year-End Corporate Update
- Asensus Surgical, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Asensus Announces Kitakyushu General Hospital in Japan to Initiate Second Senhance System
- Asensus Surgical: Kitakyushu General Hospital to initiate second Senhance System